PRODUCT Properties
| Melting point: | 148-150?C |
| Boiling point: | 435.8±45.0 °C(Predicted) |
| Density | 1.4132 (rough estimate) |
| refractive index | 1.6200 (estimate) |
| storage temp. | 2-8°C |
| solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 13.84±0.46(Predicted) |
| color | White to Off-White |
| InChI | InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) |
| InChIKey | GIYAQDDTCWHPPL-UHFFFAOYSA-N |
| SMILES | C(NCCN(CC)CC)(=O)C1=CC(Br)=C(N)C=C1OC |
Description and Uses
Bromopride is a dopamine D2 receptor antagonist (Ki = 14 nM). It binds to bovine anterior pituitary membranes with an IC50 value of 2.13 μM. Bromopride inhibits cholinesterase activity in vitro in rat plasma and striatum homogenate (IC50s = 67.8 and 38.4 μM, respectively). It increases serum prolactin levels in rats by 100% when used at a dose of 0.02 mol/kg. Bromopride (2.5 mg/kg) decreases locomotion and rearing in an open field test and impairs acquistion, but not retention, of a conditioned avoidance response in a two-way active conditioned avoidance test in rats.
An antiemetic.Bromopride is used in method and a system for analyzing neuropharmacology of a drug.
